Back to top

Champions Oncology (CSBR) Soars: Stock Adds 10.7% in Session

Read MoreHide Full Article

Champions Oncology, Inc. (CSBR - Free Report) was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $8.20–$17.47 in the past one-month time frame, showed a sharp increase yesterday.

The company has seen one positive estimate revision in the past month, while its Zacks Consensus Estimate for the current quarter has also moved higher over the same time frame, suggesting that more solid trading could be ahead for Champions Oncology. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Champions Oncology currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.  

Another stock worth considering in the Medical – Drugs industry is BioSpecifics Technologies Corp. (BSTC - Free Report) which also carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Is CSBR going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Champions Oncology, Inc. (CSBR) - free report >>

BioSpecifics Technologies Corp (BSTC) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in